Inhalation Sciences ships major order worth approx. 3 MSEK to new US big pharma client
Inhalation Sciences (ISAB) has shipped a major order, originally announced in December 2019, to a big pharma client in the US. The order includes a PreciseInhale® aerosol generator and a DissolvIt® in vitro tool, the third such module to ship within weeks of its recent commercial launch.
“The preliminary revenue numbers for Q1, including this shipment, is 5,7 MSEK. This would mean the best quarter in ISAB’s history from a revenue point of view” says ISAB CEO Manoush Masarrat, “for our team to realize this shipment now, despite the present uncertainties and challenges over COVID-19, proves their outstanding professionalism and commitment.”
The order comes from a leading pharmaceutical company. It is their first instrument order placed with Inhalation Sciences. The buyer has an extensive pipeline and this PreciseInhale-system is planned to be used at one of its US-based facilities. It is the second PreciseInhale to be shipped to the US. The total order is worth 317,000 USD. As well as PreciseInhale and DissolvIt it includes an intratracheal exposure module and a Nose-Only exposure module.
“This confirms how many more companies are recognizing that the data PreciseInhale delivers can really put them in the lead,” says CEO Manoush Masarrat.
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when being inhaled.
The information above was provided by Inhalation Sciences Sweden AB (publ) for publication on April 1, 2020.
Tags: